Summit Therapeutics' Ivonescimab Shows Superiority in Biliary Tract Cancer Trial
Event summary
- Summit Therapeutics' partner Akeso's Phase III HARMONi-GI1 trial showed ivonescimab plus chemotherapy significantly improved overall survival in advanced biliary tract cancer compared to durvalumab plus chemotherapy.
- The trial, conducted in China, met all primary and secondary endpoints, including progression-free survival and objective response rate.
- Data will be presented at ESMO 2026 Presidential Symposium on October 25, 2026.
- Ivonescimab is approved in China for non-small cell lung cancer but remains investigational in Summit's license territories.
- Over 5,000 patients have been treated with ivonescimab in clinical studies globally.
The big picture
This trial success positions ivonescimab as a potential first-in-class therapy, combining immunotherapy and anti-angiogenesis in a single molecule. The results could reshape treatment paradigms for biliary tract cancer, a disease with limited therapeutic options. Summit's ability to capitalize on this data will depend on regulatory approvals and commercial execution in key markets.
What we're watching
- Regulatory Pathway
- Whether Summit can leverage these results to accelerate ivonescimab's approval in the U.S. and Europe, where it remains investigational.
- Commercialization Strategy
- How Summit plans to position ivonescimab against existing therapies in biliary tract cancer and other indications.
- Pipeline Expansion
- The pace at which Summit and Akeso advance additional Phase III trials for ivonescimab in other cancer types.